Valuation: AbCellera Biologics Inc.

Market Cap 3.83B 3.42B 3.16B 2.86B 5.36B 364B 5.45B 38.02B 15.05B 191B 14.37B 14.07B 601B P/E 2026 *
-17.7x
P/E 2027 * -15.7x
Enterprise Value 3.66B 3.27B 3.02B 2.74B 5.12B 348B 5.21B 36.36B 14.4B 182B 13.75B 13.45B 574B EV / Sales 2026 *
139x
EV / Sales 2027 * 131x
Free-Float
78.26%
Yield 2026 *
-
Yield 2027 * -
1 day+3.96%
1 week+0.17%
Current month-18.99%
1 month-3.98%
3 months+108.47%
6 months+191.85%
Current year+245.61%
1 week 11.08
Extreme 11.08
12.36
1 month 11.08
Extreme 11.08
15.02
Current year 2.74
Extreme 2.745
15.02
1 year 2.74
Extreme 2.745
15.02
3 years 1.89
Extreme 1.8906
15.02
5 years 1.89
Extreme 1.8906
17.93
10 years 1.89
Extreme 1.8906
71.91
Manager TitleAgeSince
Chief Executive Officer 51 2012-11-07
Chief Operating Officer 41 2012-11-07
Director of Finance/CFO 52 2019-07-31
Director TitleAgeSince
Chairman 51 2012-11-07
Director/Board Member 41 2012-11-07
Director/Board Member 74 2019-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/24/26 Buy

Director

53,613 0.0176%
8/18/26 Buy

Director

10,000 0.0033%
8/14/26 Buy

Chief Financial Officer

37,200 0.0122%
Change 5-day change 1-year change 3-year change Capi.($)
+3.96%+0.17%+107.01%+176.81% 3.68B
+2.41%+0.29%+42.02%+71.57% 63.29B
-0.15%+7.50%+11.01%+73.48% 54.89B
+0.57%+4.60%+10.07%+92.86% 53.28B
+0.37%+4.67%+27.03%+52.07% 45.81B
-1.21%+2.32%+21.80%+123.81% 43.46B
-0.37%+5.07%+249.91%+918.74% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+4.55%+37.71%+28.10% 23.76B
Average +0.64%+0.61%+54.89%+159.35% 38.56B
Weighted average by Cap. +0.41%+2.15%+47.92%+159.35%

Financials

2026 *2027 *
Net sales 26.37M 23.55M 21.75M 19.71M 36.88M 2.5B 37.49M 262M 104M 1.31B 98.95M 96.85M 4.13B 28.24M 25.22M 23.3M 21.11M 39.5M 2.68B 40.16M 280M 111M 1.4B 106M 104M 4.43B
Net income -208M -185M -171M -155M -290M -19.7B -295M -2.06B -816M -10.32B -779M -762M -32.55B -245M -219M -202M -183M -342M -23.23B -348M -2.43B -962M -12.17B -918M -899M -38.37B
Net Debt -168M -150M -138M -125M -234M -15.91B -238M -1.66B -659M -8.33B -629M -615M -26.27B -118M -105M -97.04M -87.94M -165M -11.17B -167M -1.17B -462M -5.85B -441M -432M -18.45B
Projected Income Statement - Annual - AbCellera Biologics Inc.
Logo AbCellera Biologics Inc.
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Employees
562
Date Price Change Volume
26-10-23 US$11.82 +3.96% 3,026,127
26-10-22 US$11.37 -7.11% 4,277,110
26-10-21 US$12.24 +4.53% 3,216,083
26-10-20 US$11.71 -1.84% 4,263,275
26-10-19 US$11.93 +1.10% 3,136,991
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - AbCellera Biologics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
11.82USD
Average target price
16.82USD
Spread / Average Target
+42.29%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AbCellera Biologics Inc.
  1. Stock Market
  2. Stocks
  3. ABCL Stock